There’s nowhere to hide after today’s ZIMV bloodbath. Can’t have sales decline 7% yoy the same quarter we launch two new implants. Please do an all sales call and tell us what Nan does right.
There’s nowhere to hide after today’s ZIMV bloodbath. Can’t have sales decline 7% yoy the same quarter we launch two new implants. Please do an all sales call and tell us what Nan does right.
It’s a simple question you need to have the answer prepared to convince the OMS/Perio etc to consider switching to your new implant: What deficiency does the new implant address of my implant practice? Is it an increase in success rate that hovers above 95%? Is it greater primary stability, because most systems allow for immediate non occlusal temporization. Is it tissue response or ease of use in the restorative phase? Thanks to iOS, most system have a solution.
Point is, unless you have a unique purpose within this space, any new intro will fall flat.
It won’t be implant companies buying others, it will be software companies selling a package for complex cases thanks to digital and robotics entering the dental space. Simple cases will follow along as this method will become the standard of care. Nobel one time had the right idea, but introduced the solution poorly and too early. Give it 18 months, you will see the tech space step in.
